All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Key communications on GvHD at EHA 2021

During the EHA2021 Virtual Congress, the GvHD Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What were the key communications on GvHD at EHA 2021?

Key communications on GvHD at EHA 2021

In this video, Mohty highlights two key presentations from EHA 2021. The first one being the phase III INTEGRATE trial of ibrutinib combined with corticosteroids in previously untreated patients with chronic GvHD. While the second communication was a subgroup analysis of the REACH2 trial evaluating the efficacy and safety of ruxolitinib in patients with steroid-refractory acute GvHD who crossed over from the best alternative treatment.

 

Share: